Long-term efficacy of Interferon-α and ursodeoxycholic acid in treatment of chronic type C hepatitis

Digestive Diseases and Sciences

Volumn 42, Issue 7, 1997, Pages 1438-1444

  Senturk, Hakan ^a   Uzunalimoglu, Ozden ^a   Batur, Yucel ^a   Simsek, Ilkay ^a   Mert, Ali ^a   Ozbay, Gulsen ^a   Cetinkaya, Hulya ^a   Ersoz, Galip ^a   Tabak, Fehmi ^a   Akbaylar, Hale ^a   Akdogan, Meral ^a   Dokmeci, Abdulkadir ^a   Sonsuz, Abdullah ^a   Ozenirler, Seren ^a   Erden, Esin ^a   Tozum, Nurdan ^a  

^a NONE

Author keywords

Hepatitis C; Interferon ; Ursodeoxycholic acid

Indexed keywords

ALPHA INTERFERON; URSODEOXYCHOLIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHOLAGOGUES AND CHOLERETICS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME TESTS; FEMALE; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 8544226947     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018854424403     Document Type: Article

References (38)

1. Kiyosawa K, Akahane Y, Nagata A, Koike Y, Furuta S: Significance of blood transfusion in non-A, non-B chronic liver disease in Japan. Vox Sanguinis 43:45-52, 1982
2. DiBisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter, HJ: Long-term clinical and histopathologic follow-up of chronic posttransfusion hepatitis. Hepatology 14:969-974, 1991
3. Takashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T: Natural course of chronic hepatitis C. Am J Gastroenterol 88:240-243, 1993
4. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463-1466, 1995
5. Sceff LB, Buskell-Bales Z, Wright EC, et al: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 327:1906-1911, 1992
6. DiBisceglie AM, Martin P, Kassianides C, et al: Recombinant interferon alfa therapy for chronic hepatitis C: A randomized double-blind, placebo controlled trial. N Engl J Med 321:1506-1510, 1989
7. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989
8. Marcellin P, Boyer N, Giostra E: Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 13:393-397, 1991
9. Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A: The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 23(suppl 2):8-12, 1995
10. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S: Treatment of chronic hepatitis C with high dose interferon alpha-2b: A multicenter study. Dig Dis Sci 38:612-618, 1993
11. Chemello L, Bonetti P, Cavaletto L, et al: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 22:700-706, 1995
12. Poynard T, Bedossa P, Chevallier M, et al: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457-1462, 1995
13. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K: A controlled study to determine the optimal dose regimen of interferon-a 2b in chronic hepatitis C. Am J Gastroenterol 90:1246-1249, 1995
14. Attili AF, Rusticali A, Varriale M, Carli L, Repice AM, Callea F: The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. J Hepatol 20:315-320, 1994
15. Bellentani S, Podda M, Tiribelli C, et al: Ursodiol in the long-term treatment of chronic hepatitis: A double-blind multicenter clinical trial. J Hepatol 19:459-464, 1993
16. Boucher E, Jouanolle H, Andre P, et al: Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 21:322-327, 1995
17. Angelico M, Gandin C, Pescarmona E, et al: Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: A randomized clinical trial with long-term follow-up. Am J Gastroenterol 90:63-69, 1995
18. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Ann Biochem 162:156-159, 1987
19. Shindo M, Di Bisceglie A, Cheung L, et al: Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis. Ann Intern Med 115:700-704, 1991
20. Okamoto H, Sugiyama Y, Okada S, et al: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 73:673-679, 1992
21. Simmonds P, Holmes EC, Cha TA, et al: Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5′ region. J Gen Virol 74:2391-2399, 1993
22. McOMish F, Yap PL, Dow BC, et al: Geographical distribution of hepatitis C virus genotypes in blood donors; an international collobrative survey. J Clin Microbiol 32(4):S84-892, 1994
23. Lau JYN, Mizokami M, Ohto T, Diamond DA, Kniffen J, Davis GL: Discrepancy between biochemical and virologic responses to interferon-α in chronic hepatitis C. Lancet 324:1208-1209, 1993
24. Mohler CM, Seipp S, Tox U, Stremmel W, Theilmann L, Goeser T: Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis. Dig Dis Sci 41:1266-1267, 1996
25. Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, Vlahcevic ZR: Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. Gastroenterology 100:203-211, 1991
26. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A: Ursodeoxycholate reduces hepatotoxicty of hile salts in primary human hepatocytes. Hepatology 12:486-491, 1990
27. Marcellin P, Boyer N, Degott C, et al: Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon. Liver 14:302-307, 1994
28. Chemello L, Cavalletto L, Casarin C, et al: Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med 124:1058-1060, 1996
29. Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B: High-dose interferon-a2b for retreatment of nonresponders or relapsing patients with chronic hepatitis C: A controlled randomized trial. Dig Dis Sci 41:149-154, 1996
30. Esteban JI, Lopez-Talavera JC, Genesca J, et al: High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 115:443-449, 1991
31. Naito M, Hayashi N, Hagiwara H, et al: Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 19:871-875, 1994
32. Prieto M, Olaso V, Verdu C, et al: Does the healthy hepatitis C virus carier state really exist? An analysis using polymerase chain reaction. Hepatology 22:413-417, 1995
33. Shindo M, Arai K, Sokawa Y, Okuno T: The virological and histological states of antihepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 22:418-425, 1995
34. Simmonds P, Mellor J, Craxi A, et al: Epidemiological, clinical, and therapeutic associations of hepatitis C types in western European patients. J Hepatol 24:517-524, 1996
35. Bellary S, Smith DG, Bankes P, Harris A, Shayiq R, Black M: High dose interferon α-2b therapy for chronic hepatitis C: An open label study of the response and predictors of response. Am J Gastroenterol 90:259-262, 1995
36. Hiramatsu N, Hayashi N, Kasahara A, et al: Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 22:135-142, 1995
37. Roffi L, Mells GC, Antonelli G, et al: Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection; prevalence, etiology, and management. Hepatology 21:645-649, 1995
38. Lebovics E, Lantin J, Chaurushia G, Dworkin BM, Casellas A, Rosenthal WS: The breakthrough phenomenon during α-interferon therapy of chronic hepatitis C: incidence, management, and outcome. Am J Gastroenterol 90:951-954, 1995